Erratum to: Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment
نویسندگان
چکیده
منابع مشابه
Prevalence of Fatty Liver in Breast Cancer Patients Undergoing Treatment
Background and purpose: Fatty liver is one of the most common liver diseases. Some treatments used in breast cancer may be associated with development of fatty liver. The present study aimed at investigating the prevalence of fatty liver in breast cancer patients. Materials and methods: In this cross-sectional study, 117 patients with breast cancer attending Ramsar Imam Sajjad Hospital in 2017...
متن کاملPrognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment: Erratum
متن کامل
modern surgical techniques in treatment of patients with cleft lip & cleft palate
چکیده ندارد.
15 صفحه اولRelationship between the expression of miR137 in the serum of patients with metastatic lung cancer
Background: Micro-Ribonocellic Acids (miRNA) are non-coding nucleic acids that are evolutionally protected and have a length of 24-20 nucleotides. MiRNAs control the expression of genes after transcription by mRNA degradation or translation inhibition. By blocking the oncogenic miRNAs and creating the necessary and functional miRNAs (tumor suppressor), these small regulatory RNAs can have thera...
متن کاملEvaluation of pre-treatment serum levels of IL-7 and GM-CSF in colorectal cancer patients
Background: Survival of Colorectal cancer (CRC) patients is considerably stage-dependent therefore, early diagnosis is a pivotal factor in decreasing mortality and morbidity associated with this cancer. GM-CSF and IL-7 are reported to increase in different cancers and we aim to investigate the pre-treatment serum levels of GM-CSF and IL-7 in Iranian patients with colorectal cancer. Methods: ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Metabolomics
سال: 2016
ISSN: 1573-3882,1573-3890
DOI: 10.1007/s11306-016-1068-8